Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):971–981. doi: 10.1002/pds.1637

Table 2.

Characteristics of patients receiving QT-prolonging drugs

      All patients (n=6125) QT-prolonging drugs not coadministered (n=4986) QT-prolonging drugs coadministered (n=1139) p-value1
Age (years) (±SE) 63.0 (±0.2) 62.8 (±0.20) 63.5 (±0.5) 0.474
Gender (% male) 55.4 54.5 59.2 0.005
Ethnicity (%) 0.955
  Caucasian 84.4 84.2 85.4
  African American 8.3 8.4 8.0
  Latin/Hispanic 4.5 4.6 4.3
  Not specified/Other 2.7 2.8 2.3
ICU Mortality Rate (%) 11.8 10.9 16.0 <0.001
ICU LOS (days) (mean±SE) 8.4 (±0.1) 7.2 (±0.12) 13.3 (±0.4) <0.001
Pre-existing disease (%)
  Cardiac 13.2 13.8 10.5 0.004
  Respiratory 10.2 10.1 10.7 0.610
  Renal 3.2 3.3 2.5 0.195
  Gastrointestinal 3.8 3.8 3.8 0.998
1

Refers to comparison between patients not receiving and receiving coadministered QT-prolonging drugs

HHS Vulnerability Disclosure